Investment
Features
FeesSafety
Academy
More
Pluang+

Compare EHang Holdings Ltd - ADR (EH) vs GSK plc (GSK) Price & Performance

EHang Holdings Ltd - ADRTrade

Price performance (Past 24H)

Key statistics

EHang Holdings Ltd - ADR vs GSK plc — how do they compare? EHang Holdings Ltd - ADR trades at $5.66 (market cap $437.63M), while GSK plc trades at $50.39 (market cap $102.60B). The key difference: GSK plc is far larger — about 234.4× EHang Holdings Ltd - ADR's market cap, and GSK plc pays a 3.57% dividend while EHang Holdings Ltd - ADR pays none. Which is the better fit depends on your goals.

EHGSK
Market Cap
$437.63M$102.60B
Sector
IndustrialsHealth
52-Week High
$19.44$61.18
52-Week Low
$4.90$38.22
Enterprise Value
$376.84M$123.04B
Dividend Yield
3.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

EHang Holdings Ltd - ADR

EHang Holdings (EH) trades at $5.66, down 0.53% on the day, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The company reported Q1 2026 revenue of $418 million, but net losses persist with a margin of -77.57%. Recent news includes the successful pilotless eVTOL flight in Kazakhstan, highlighting operational progress amid financial challenges.

The stock presents high-risk potential with analyst consensus divided and a price target of $6.97. Investment appeal hinges on commercialization success and cost management, but substantial losses and competitive pressures pose significant risks to near-term shareholder value.

GSK plc

GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.

GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About EHang Holdings Ltd - ADR

EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.

Read more on EH

About GSK plc

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Read more on GSK